Xarelto is owned by Janssen Pharms.

Xarelto contains Rivaroxaban.

Xarelto has a total of 8 drug patents out of which 0 drug patents have expired.

Xarelto was authorised for market use on 01 July, 2011.

Xarelto is available in tablet;oral dosage forms.

Xarelto can be used as reducing the risk of stroke and systemic embolism; treatment of pulmonary embolism (pe); treatment of deep vein thrombosis (dvt); reduction of risk of major cardiovascular events (cv death, mi, and stroke) in chronic cad or pad; prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding; prophylaxis of thromboembolic diseases in pediatric patients aged 2 years and older with congenital heart disease who have undergone the fontan procedure and a body weight of >=50 kg; treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of 30 kg to 49.9 kg after at least 5 days of initial parenteral anticoagulant treatment; reduction in the risk of recurrence of deep vein thrombosis (dvt) and/or pulmonary embolism (pe) in patients at continued risk for recurrent dvt and/or after completion of initial treatment lasting at least 6 months; prophylaxis of deep vein thrombosis (dvt); reduction of risk of major cardiovascular events (cardiovascular death, myocardial infarction and stroke) in patients with cad; reduction of risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of vascular etiology) in patients with pad; treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of >=50 kg after at least 5 days of initial parenteral anticoagulant treatment, treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; after completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment, reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily.

The generics of Xarelto are possible to be released after 31 July, 2039.